American Society of Hematology (ASH) Annual Meeting Orlando, Florida, USA. 7-10 December 2019

American Society of Hematology (ASH) Annual Meeting
Orlando, Florida, USA. 7-10 December 2019
 
ASH 2019 myeloma highlights

More than 900 myeloma abstracts (posters and oral sessions) were presented in the largest world congress of hematology: the American Society of Hematology (ASH) Annual Meeting 2019 that was held from 7 to 10 December 2019 in Orlando, Florida, USA. Dr Faith Davies, NYU Langone Hospital, New York, USA, summarises in this video the most important myeloma updates presented at ASH 2019.
 

ASH 2019 AL amyloidosis highlights

Dr Moshe Gatt, Hadassah Hebrew University Medical Center, Jerusalem (Israel) summarised for Myeloma Patients Europe (MPE) the main updates on AL amyloidosis presented at the American Society of Hematology (ASH) Annual Meeting held from 7 to 10 December 2019 in Orlando, Florida, USA.
 

Positive results of the clinical trial Candor at ASH 2019

ASH 2019 – Orlando. The big “late-breaking” news at the American Society of Hematology Annual Meeting are the results of the phase III Candor trial. Dr Katja Weisel, University Medical Center Hamburg-Eppendorf in Germany, explains for Myeloma Patients Europe (MPE) in this video the main results of this clinical trial.
 

ASH 2019 CAR-T cell therapy in myeloma

CAR-T cell therapy is one of the most promising treatments in a number of types of cancer. In myeloma, very promising results were presented during the American Society of Hematology (ASH) Annual Meeting. Dr Mohamad Mohty, Head of Haematology and and celular therapy department, Saint-Antoine Hospital and University Pierre & Marie Curie, Paris, France, summarises for Myeloma Patients Europe (MPE) the most important CAR-T cells updates in myeloma at ASH.
Second-generation CAR T-cell products may overcome resistance, reduce toxicity and simplify treatment

ASH 2019, Orlando – A number of early-phase studies were presented yesterday during the 61st American Society of Hematology (ASH) Annual Meeting spotlight the rapid advances being made in cellular immunotherapy for blood cancers. Researchers will present the results of early-phase studies of emerging “second-generation” cellular immunotherapy products that strive to overcome the limitations of existing products.
Read more…
 

ASH 2019 updates on Minimal Residual Disease (MRD)
Minimal Residual Disease (MRD) is one of the big topics in myeloma. Different techniques to measure MRD and new data about its role in predicting the risk of relapse are some of the topics discussed during the American Society of Hematology (ASH) Annual Meeting. In this video Dr Francesca Gay, University of Torino, Italy, explains for Myeloma Patients Europe (MPE) what was presented at ASH 2019 regarding MRD and the unanswered questions about its role as a surrogate endpoint.
Read more…
 

Breaking the glass ceiling of age in transplant in myeloma
ASH 2019, Orlando – Even though autologous hematopoietic cell transplantation (AHCT), a form of stem cell therapy, is an effective treatment for multiple myeloma, only four out of 10 patients receive this therapy. Myeloma occurs most often in people over 60 and the age is usually the main reason for avoiding this procedure. A new study presented in the 61st American Society of Hematology Annual Congress shows this procedure is safe and effective in older patients and suggests that more people could benefit from the therapy than have typically been offered it.
Real World Evidence at ASH 2019
Real World Evidence (RWE) is becoming more and more important not only for clinicians but also for scientific meetings such as the American Society of Hematology (ASH) Annual Meeting. Dr Faith Davies, NYU Langone Hospital, New York, USA, summarises in this video the most important updates regarding Real World Evidence in myeloma presented at ASH 2019.
Read more…

Bispecific antibodies at ASH 2019
Along with CAR-T cell treatment, bispecific antibodies has been one of the most important topics discussed at the American Society (ASH) Annual Meeting. This family of drugs has shown very promising results in early phases of clinical trials in heavily pre-treated myeloma patients. Dr Mohamad Mohty, Head of Haematology and and Celular Therapy Department, Saint-Antoine Hospital and University Pierre & Marie Curie, Paris, France, summarises for Myeloma Patients Europe (MPE) the most important updates on bispecific antibodies at ASH 2019.
Read more…

Positive results of selinexor in relapsed and refractory myeloma patients presented at ASH 2019
Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound that is approved the United States Food and Drug Administration (FDA) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. During the American Society of Hematology (ASH) Annual Meeting, new results of this myeloma drug were presented. Dr Cristina Gasparetto, Duke Cancer Institute, North Corolina, USA, explains for Myeloma Patients Europe (MPE) the main results of selinexor.
Read more…

New data show HARMONY Alliance’s big data platform can improve the prognostic tool for myeloma patients
ASH 2019, Orlando – New data presented by the HARMONY Alliance validate the current prognostic tool for Multiple Myeloma and have identified new parameters to improve the staging of the disease according to a press release publish by the Harmony Alliance. Myeloma Patients Europe (MPE) is part of the HARMONY Patient Cluster which is a unique group of 7 European Patient Umbrella Organizations working in the different areas of hematological diseases within the HARMONY Alliance.
Read more…

Dreamm-3, the clinical trial on the new myeloma drug belantamab mafodotin, presented at ASH 2019
ASH 2019, Orlando – Belantamab mafodotin is a new myeloma drug that has shown very promising results. The clinical trial Dreamm-3 was presented yesterday at the American Society of Hematology (ASH) Annaul Congress and it is expected to be the European approval trial for this drug. Dr Katja Weisel, University Medical Center Hamburg-Eppendorf in Germany, explains for Myeloma Patients Europe (MPE) what we need to know about this first-in-class drug.
ASH 2019 Pre-clinical myeloma updates

Dr Faith Davies, NYU Langone Hospital, New York, USA, explains in this video the pre-clinical myeloma updates presented in the American Society of Hematology (ASH) Annual Meeting 2019 and why are those important to patients.
 

Webinar on ASH 2019
14 January
Myeloma Patients Europe will hold a webinar to review the most recent myeloma findings presented at ASH 2019 on Tuesday 14 January (18:00-19:00 PM CET). The talk will be given by Dr Moshe Gatt, Hadassah Hebrew University Medical Center, Jerusalem (Israel). Register now!
More information

MPE AGM 2020
Amsterdam, 6-8 March
Once a year MPE holds its Annual General Meeting (Masterclass and AGM General Assembly). All MPE members and sponsors are invited to this event which includes a one-and-a-half day Masterclass to provide training to MPE members with scientific sessions, given by the most important specialists in Europe, and advocacy sessions. Register now!
More information
 

Would you like to get involved in MPE patient-focused activities and research? Find more information in this link and complete the form
Twitter
Facebook
YouTube
Myeloma Patients Europe
 
Copyright © 2019 Myeloma Patients Europe, All rights reserved.
Myeloma Patients Europe AISBL newsletter subscription

Our mailing address is:

Myeloma Patients Europe

Avenue Louise 149/24 1050 Brussels Belgium

Brussels 1050

Belgium